Genetic Polymorphs and Molecular Biomarkers: Infliximab and Beyond
Infliximab utility marks a monumental shift in the treatment of autoimmune diseases.
The exploration of glucagon-responsive micelles and polymer conjugates offers a promising advancement in the field of diabetes management.
Targeted liposomal therapeutics mark a shift toward precise and less toxic disease treatments.
The development of targeted liposomal therapeutics represents a significant leap forward in drug delivery systems.
As cancer care marches forward, fostering diversity in clinical trials stands as a non-negotiable imperative.
The future of drug discovery is increasingly moving toward personalized therapies.
Biopharma PEG announces a groundbreaking array of monodispersed PEGs to propel the pharma industry into a new era.
Huateng Pharma has unveiled a suite of advanced anti-diabetes intermediates, featuring compounds intricately designed to target diabetes with unprecedented precision.
Takara Bio collaborates with Fondazione Telethon ETS in a RetroNectin® license agreement.
Infliximab utility marks a monumental shift in the treatment of autoimmune diseases.
Rheumatoid arthritis remains a challenging disease with a complex etiology.
The recent breakthrough in replicating Lewy body formation in living human neurons marks a pivotal moment in Parkinson’s research.
Parkrun has emerged as a potential answer to a global public health burden – physical inactivity.
22nd of October, 2024
Learn more23rd of October, 2024
Learn more11th of November, 2024
Learn more12th of November, 2024
Learn more13th of November, 2024
Learn more14th of November, 2024
Learn more14th of May, 2024
Learn more15th of May, 2024
Learn more16th of May, 2024
Learn more21st of May, 2024
Learn more22nd of May, 2024
Learn more23rd of May, 2024
Learn moreThis website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings